TY - JOUR AU - Zhang, Hailong AU - Zheng, Yajuan AU - Pan, Youdong AU - Lin, Changdong AU - Wang, Shihui AU - Yan, Zhanjun AU - Lu, Ling AU - Ge, Gaoxiang AU - Li, Jinsong AU - Zeng, Yi Arial AU - Chen, Jianfeng PY - 2020 DA - 2020/06/10 TI - A mutation that blocks integrin α4β7 activation prevents adaptive immune-mediated colitis without increasing susceptibility to innate colitis JO - BMC Biology SP - 64 VL - 18 IS - 1 AB - β7 integrins are responsible for the efficient recruitment of lymphocytes from the blood and their retention in gut-associated lymphoid tissues. Integrin α4β7 binds MAdCAM-1, mediating rolling adhesion of lymphocytes on blood vessel walls when inactive and firm adhesion when activated, thereby controlling two critical steps of lymphocyte homing to the gut. By contrast, integrin αEβ7 mediates the adhesion of lymphocytes to gut epithelial cells by interacting with E-cadherin. Integrin β7 blocking antibodies have shown efficacy in clinical management of inflammatory bowel disease (IBD); however, fully blocking β7 function leads to the depletion of colonic regulatory T (Treg) cells and exacerbates dextran sulfate sodium (DSS)-induced colitis by evoking aberrant innate immunity, implying its potential adverse effect for IBD management. Thus, a better therapeutic strategy targeting integrin β7 is required to avoid this adverse effect. SN - 1741-7007 UR - https://doi.org/10.1186/s12915-020-00784-6 DO - 10.1186/s12915-020-00784-6 ID - Zhang2020 ER -